Skip to main content

Advertisement

Table 2 89 Zr-bevacizumab uptake parameters

From: Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

  Tumorous tissue Blood (AD) Non-tumorous tissue
PT LNM NLNM Muscle Fat Lung
Day 4        
 SUVpeak 4.3 4.0 5.0 3.9 1.0 0.6 0.8
(2.1 to 6.9) (2.1 to 12.1) (2.9 to 14.5) (1.7 to 4.9) (0.4 to 1.1) (0.3 to 0.7) (0.5 to 1.4)
 TBR 1.2 1.1 1.2   0.3 0.2 0.3
(0.7 to 1.8) (0.8 to 7.2) (0.7 to 8.6)   (0.1 to 0.3) (0.1 to 0.2) (0.2 to 0.3)
Day 7        
 SUVpeak 3.3 2.7 3.9 1.4 0.5 0.4 0.4
(0.7 to 4.9) (1.0 to 9.0) (1.1 to 9.7) (0.9 to 3.5) (0.2 to 1.3) (0.1 to 0.6) (0.2 to 1.1)
 TBR 0.8 1.6 1.9   0.5 0.3 0.4
(1.0 to 4.0) (1.1 to 15.3) (0.9 to 16.5)   (0.3 to 0.6) (0.1 to 0.4) (0.2 to 0.6)
  1. AD, aorta descendens; LNM, lymph node metastases; NLNM, non-lymph node metastases; PT, primary tumor; TBR, tumor-to-blood ratio. Median (range) is shown.